Cancer Research Cancer Health Disparities Conference 2009  SU2C
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Smith, H. J.
Right arrow Articles by Tisdale, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smith, H. J.
Right arrow Articles by Tisdale, M. J.
[Cancer Research 64, 8731-8735, December 1, 2004]
© 2004 American Association for Cancer Research


Regular Articles

Mechanism of the Attenuation of Proteolysis-Inducing Factor Stimulated Protein Degradation in Muscle by ß-Hydroxy-ß-Methylbutyrate

Helen J. Smith, Stacey M. Wyke and Michael J. Tisdale

Pharmaceutical Sciences Research Institute, Aston University, Birmingham, United Kingdom

The leucine metabolite ß-hydroxy-ß-methylbutyrate (HMB) prevents muscle protein degradation in cancer-induced weight loss through attenuation of the ubiquitin-proteasome proteolytic pathway. To investigate the mechanism of this effect, the action of HMB on protein breakdown and intracellular signaling leading to increased proteasome expression by the tumor factor proteolysis-inducing factor (PIF) has been studied in vitro using murine myotubes as a surrogate model of skeletal muscle. A comparison has been made of the effects of HMB and those of eicosapentaenoic acid (EPA), a known inhibitor of PIF signaling. At a concentration of 50 µmol/L, EPA and HMB completely attenuated PIF-induced protein degradation and induction of the ubiquitin-proteasome proteolytic pathway, as determined by the "chymotrypsin-like" enzyme activity, as well as protein expression of 20S proteasome {alpha}- and ß-subunits and subunit p42 of the 19S regulator. The primary event in PIF-induced protein degradation is thought to be release of arachidonic acid from membrane phospholipids, and this process was attenuated by EPA, but not HMB, suggesting that HMB might act at another step in the PIF signaling pathway. EPA and HMB at a concentration of 50 µmol/L attenuated PIF-induced activation of protein kinase C and the subsequent degradation of inhibitor {kappa}B{alpha} and nuclear accumulation of nuclear factor {kappa}B. EPA and HMB also attenuated phosphorylation of p42/44 mitogen-activated protein kinase by PIF, thought to be important in PIF-induced proteasome expression. These results suggest that HMB attenuates PIF-induced activation and increased gene expression of the ubiquitin-proteasome proteolytic pathway, reducing protein degradation.




This article has been cited by other articles:


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
H. L. Eley, S. T. Russell, J. H. Baxter, P. Mukerji, and M. J. Tisdale
Signaling pathways initiated by beta-hydroxy-beta-methylbutyrate to attenuate the depression of protein synthesis in skeletal muscle in response to cachectic stimuli
Am J Physiol Endocrinol Metab, October 1, 2007; 293(4): E923 - E931.
[Abstract] [Full Text] [PDF]


Home page
Integr Cancer TherHome page
M. F. McCarty and K. I. Block
Toward a core nutraceutical program for cancer management.
Integr Cancer Ther, June 1, 2006; 5(2): 150 - 171.
[Abstract] [PDF]


Home page
Nutr Clin PractHome page
R. Siddiqui, D. Pandya, K. Harvey, and G. P. Zaloga
Nutrition Modulation of Cachexia/Proteolysis
Nutr Clin Pract, April 1, 2006; 21(2): 155 - 167.
[Abstract] [Full Text] [PDF]


Home page
Nutr Clin PractHome page
M. J. Tisdale
Clinical Anticachexia Treatments
Nutr Clin Pract, April 1, 2006; 21(2): 168 - 174.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
V. E. Baracos and M. L. Mackenzie
Investigations of Branched-Chain Amino Acids and Their Metabolites in Animal Models of Cancer
J. Nutr., January 1, 2006; 136(1): 237S - 242S.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.